Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) EBT Margin (2020 - 2026)

Maxcyte has reported EBT Margin over the past 6 years, most recently at 201.22% for Q4 2025.

  • Quarterly EBT Margin rose 32312.0% to 201.22% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 212.96% through Dec 2025, down 8806.0% year-over-year, with the annual reading at 212.96% for FY2025, 10667.0% down from the prior year.
  • EBT Margin was 201.22% for Q4 2025 at Maxcyte, up from 181.81% in the prior quarter.
  • Over five years, EBT Margin peaked at 201.22% in Q4 2025 and troughed at 428.75% in Q4 2021.
  • The 5-year median for EBT Margin is 117.27% (2023), against an average of 100.41%.
  • Year-over-year, EBT Margin plummeted -54391bps in 2021 and then skyrocketed 40808bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 428.75% in 2021, then skyrocketed by 95bps to 20.67% in 2022, then surged by 517bps to 86.16% in 2023, then plummeted by -241bps to 121.9% in 2024, then skyrocketed by 265bps to 201.22% in 2025.
  • Per Business Quant, the three most recent readings for MXCT's EBT Margin are 201.22% (Q4 2025), 181.81% (Q3 2025), and 145.26% (Q2 2025).